Am J Transplant, Volume 16, Suppl 3 Archives - Page 54 of 180 - ATC Abstracts

2016 American Transplant Congress
Association of Smoking Habits with Comorbidity 15 Years After Liver Transplantation.
S. Pischke,³ M. Lege,¹ L. Fischer,² U. Herden,² A. Lohse,³ B. Nashan,² M. Sterneck.¹
¹University Transplant Center, University Hospital Hamburg Eppendorf, Hamburg, Germany; ²Department of Hepatobiliary Surgery and Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany; ³Department of Medicine, University Hospital Hamburg Eppendorf, Hamburg, Germany.
Background and aimsThe survival rate of liver transplant (OLT) recipients has strongly improved over the last years. Here we investigate the association between long term…
2016 American Transplant Congress
Can OPTN/UNOS Policies Be Effectively Transferred to Another Country's Healthcare System? Russian Case.
B. Yaremin,¹ A. Mironov,⁴ A. Kolsanov,² A. Navasardyan,¹ R. Akhmetshin,³ A. Starostina.²
¹Samara Regional Ministry of Health, Samara, Russian Federation; ²Operative Surgery Chair, Samara State Medical University, Samara, Russian Federation; ³Moscow Regional Ministry of Health, Moscow, Russian Federation; ⁴Samara Organ Procurement Organisation, Samara State Medical University, Samara, Russian Federation.
US Organ Procurement System known as one of the most advanced systems all over the World. Start of new transplant program in other country always…
2016 American Transplant Congress
Living Donor Liver Transplantation for Children With Biliary Atresia in the Pediatric End-Stage Liver Disease Era: The Role of Age and Insurance Status.
J. Chu,^1,2 R. Annunziato,³ R. Aviles,³ R. Arnon.^1,2
¹Pediatrics, Mount Sinai Medical Center, NY, NY; ²Recanati/Miller Transplantation Institute, Mount Sinai Medical Center, NY, NY; ³Psychology, Fordham University, Bronx, NY.
Lower socioeconomic status has been linked to inferior health outcomes. We have previously shown that children with biliary atresia (BA) who have public insurance (PU)…
2016 American Transplant Congress
Neutrophil-to-Lymphocyte Ratio as a Predictor of Polyomavirus BK Nephropathy in Kidney Transplant Patients.
K. Masutani,¹ A. Tsuchimoto,¹ Y. Matsukuma,¹ K. Kaku,² K. Kurihara,² Y. Okabe,² K. Tsuruya,¹ M. Nakamura,² T. Kitazono.¹
¹Department of Medicine and Clinical Science, Kyushu University, Fukuoka, Japan; ²Department of Surgery and Oncology, Kyushu University, Fukuoka, Japan.
Background: Neutrophil-to-lymphocyte ratio (NLR) is an index for systemic inflammatory response, and has been reported to be a prognostic marker in the patients with malignancies…
2016 American Transplant Congress
Comparison of Efficacy of Different Regimens for Treating Recurrent IgA Nephropathy After Kidney Transplantation.
G. Chen, C. Wang, L. Chen, J. Qiu, C. Wang, J. Fei, S. Deng, J. Li, G. Huang, Q. Fu.
Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Background Recurrent IgA nephropathy is a common complication after kidney transplantation. How to treat recipients with recurrent IgA nephropathy is still controversial. There are two…
2016 American Transplant Congress
Long-Term Renal Allograft Outcome After Parathyroidectomy.
M. Patecki, I. Scheffner, H. Haller, W. Gwinner.
Medical School Hannover, Hannover, Germany.
Parathyroidectomy (PTx) after kidney transplantation (Tx) has been reported to have adverse effects on the allograft. In this study, we analyzed the course of patients…
2016 American Transplant Congress
Diabetes Mellitus and Kidney Transplant Outcomes.
A. Mehrnia,¹ A. Wang,¹ W. Chaiwatcharayut,² E. Huang,¹ S. Bunnapradist.¹
¹Nephrology, University of California-Los Angeles, Los Angeles, CA; ²Internal Medicine, Albert Einstein University, Bronx, NY.
Background:This study investigates the impact of pre-existing (PDM) and new onset diabetes (NODAT) on the graft and patient survival after kidney transplant.Methods:The UNOS database was…
2016 American Transplant Congress
Is SVR Associated with Improved Hepatic Function in Hepatitis C Gen 1 Pts with Cirrhosis 1 Year After Completing Treatment with Sofosbuvir + Simeprevir +/- Ribavirin?
A. Modi,¹ J. Hermann,¹ H. Nazario,² S. Gonzalez,¹ J. Gripshover,³ M. Gautam,¹ J. Weinstein,² D. Potosky,³ M. Barnes,² A. Habib,² P. Mantry,² J. Trotter.¹
¹Liver Consultants of Texas, Dallas-Fort Worth, TX; ²Liver Institute Methodist, Dallas, TX; ³University of Maryland, Baltimore, MD.
Background: Combination antiviral therapy involving Sofosbuvir (SOF) & Simeprevir (SIM) +/- Ribavirin (RBV) is a relatively safe & effective Tx option in pts with gen…
2016 American Transplant Congress
The Distance Between Us: The Landscape of Recipient-Specific Loss-of-Function in Solid Organ Transplantation and Association with Rejection-Free Graft Survival.
B. Cole,^1,2,5 J. van Setten,^3,5 B. Keating.^1,4,5
¹Department of Surgery, The Penn Transplant Institute, Philadelphia, PA; ²Center for Clinical Epidemiology and Biostatistics, The Institute for Biomedical Informatics, Philadelphia, PA; ³Department of Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands; ⁴Department of Surgery, Division of Transplant, the Children's Hospital of Philadelphia, Philadelphia, PA; ⁵The Omics Working Group, iGeneTRAiN Consortium, Philadelphia, PA.
Purpose: This study aims to comprehensively identify genes that are inactivated in both copies in transplant recipients but not in their respective donors, uncovering a…
2016 American Transplant Congress
Inclusion of Human Tissue Factor Pathway Inhibitor or Thrombomodulin Transgenes Attenuates Critical Consumptive Thrombocytopenia in Cardiac Xenotransplantation.
J. Chan,¹ A. Singh,¹ P. Corcoran,¹ M. Thomas III,² B. Lewis,² D. Ayares,³ K. Horvath,¹ M. Mohiuddin.¹
¹Cardiothoracic Surgery Research Program/National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD; ²Division of Veterinary Resources, National Institutes of Health, Bethesda, MD; ³Revivicor Inc., Blacksburg, VA.
ObjectiveA major obstacle in the success of cardiac xenotransplantation has been the development of significant consumptive thrombocytopenia, frequently limiting recipient survival. Advances in genetic engineering…